GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pentixapharm Holding AG (XTER:PTP) » Definitions » Debt-to-Revenue

Pentixapharm Holding AG (XTER:PTP) Debt-to-Revenue : 0.00 (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Pentixapharm Holding AG Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Pentixapharm Holding AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.00 Mil. Pentixapharm Holding AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.00 Mil. Pentixapharm Holding AG's annualized Revenue for the quarter that ended in Jun. 2024 was €0.18 Mil. Pentixapharm Holding AG's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.00.

Pentixapharm Holding AG Debt-to-Revenue Historical Data

The historical data trend for Pentixapharm Holding AG's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pentixapharm Holding AG Debt-to-Revenue Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Revenue
- - -

Pentixapharm Holding AG Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue N/A N/A - - -

Competitive Comparison of Pentixapharm Holding AG's Debt-to-Revenue

For the Biotechnology subindustry, Pentixapharm Holding AG's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pentixapharm Holding AG's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pentixapharm Holding AG's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pentixapharm Holding AG's Debt-to-Revenue falls into.


Pentixapharm Holding AG Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Pentixapharm Holding AG's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 0.024
=0.00

Pentixapharm Holding AG's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 0.178
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.

Pentixapharm Holding AG Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pentixapharm Holding AG's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Pentixapharm Holding AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pentixapharm Holding AG (XTER:PTP) » Definitions » Debt-to-Revenue
Comparable Companies
XTER:HPHA STU:T9G XTER:MDG1 VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE UTHR MRNA NEUP SMMT OCSE:GMAB INCY BMRN
Traded in Other Exchanges
PTP:Germany PTP:Germany
Address
Robert-Rossle-Street 10, Berlin, DEU
Website
https://www.pentixapharm.com
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic.

Pentixapharm Holding AG Headlines

No Headlines